The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management

详细信息    查看全文

• 作者：C. Stephen Foster ; MD ; FACS ; FACR^a ; ^b ; ^c ; ^{sfoster@mersi.com" class="auth_mail" title="E-mail the corresponding author} ; Srishti Kothari ; DNB ; DOMS ; MNAMS^a ; ^b ; ^d ; Stephen D. Anesi ; MD^a ; ^b ; Albert T. Vitale ; MD^b ; ^e ; David Chu ; MD^b ; ^f ; ^g ; Jamie Lynne Metzinger ; MS ; MPH^a ; ^b ; Olga Ceró ; n ; MD^a ; ^b
• 关键词：uveitis ; inflammation ; immunomodulatory therapy ; immunosuppression ; corticosteroid ; ocular inflammatory disease ; biologic
• 刊名：Survey of Ophthalmology
• 出版年：2016
• 出版时间：January-February 2016
• 年：2016
• 卷：61
• 期：1
• 页码：1-17
• 全文大小：462 K

文摘

Ocular inflammatory disease is a leading cause of vision loss worldwide. Uveitis encompasses a wide spectrum of pathology, both with respect to its etiology and the anatomic location within the eye. Inflammation can be confined to the eye and may also be seen systemically. The cornerstone of management of ocular inflammatory disease historically has been corticosteroids, which are invaluable in the immediate control of inflammation; however, corticosteroids are inappropriate for long-term use as they are associated with a wide array of toxic side effects. As we continue to learn more about the various etiologies and elucidate the basic science pathways and mechanisms of action that cause intraocular inflammation, new therapeutic approaches have evolved. They include employment of immunomodulatory agents (corticosteroid-sparing therapies) that have expanded our treatment options for these vision-threatening diseases. These pharmacologics provide therapy for ocular and systemic inflammation in an individualized, patient-tailored, stepladder approach with the ultimate goal of durable, corticosteroid-free remission. We review the preferred practice patterns of a tertiary care center specializing in ocular inflammatory disease.